Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Marginalized Populations Who Are Virologically Suppressed
Clinical trial NCT04132674 · UNKNOWN
Trial details
- NCT number
- NCT04132674
- Sponsor
- Vancouver Infectious Diseases Centre
- Status
- UNKNOWN
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2018-11-26
- Primary completion
- 2020-06-30
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.